The study looks at whether a specific protein in the blood, called apolipoprotein, canpredict how much weight a person might lose after sleeve gastrectomy, a surgery forpeople with severe obesity. We want to find a specific level of this protein that showswhich patients are most likely to lose weight successfully after surgery. By identifyingthis level, we hope to guide doctors in deciding who should have the surgery and whomight do better with non-surgical weight loss methods.
The subject of our research is whether serum apolipoprotein levels can be a predictive
value for weight loss in patients who will undergo sleeve gastrectomy due to morbid
obesity. Our aim is to determine a cut-off value for patients who benefit most from
bariatric surgery based on preoperative serum apolipoprotein levels. By including this
value among the surgical indications, we plan to direct patients less likely to benefit
from surgery to conservative approaches.
Procedure: Laparoscopic Sleeve Gastrectomy
Laparoscopic Sleeve Gastrectomy
Inclusion Criteria:
- Patients aged 18 to 75
- International Classification of Diseases (ICD) code E66 diagnosis (obesity)
- Patients who have given consent for sleeve gastrectomy
- Patients who are suitable for general anesthesia
Exclusion Criteria:
- Patients who did not give consent to be included in the study
- Patients who are scheduled for surgery other than sleeve gastrectomy
Basaksehir Cam and Sakura City Hospital
Istanbul, Basaksehir, Turkey (Türkiye)
Not Provided